Quest for controls in molecular genetics.
作者信息
Grody Wayne W
机构信息
Departments of Pathology and Laboratory Medicine, Pediatrics, and Human Genetics, UCLA School of Medicine, Los Angeles, California 90095-1732, USA.
出版信息
J Mol Diagn. 2003 Nov;5(4):209-11. doi: 10.1016/S1525-1578(10)60475-8.
Abstract
摘要
相似文献
1
Quest for controls in molecular genetics.
J Mol Diagn. 2003 Nov;5(4):209-11. doi: 10.1016/S1525-1578(10)60475-8.
2
[From physical mapping of the genes to functional analysis of the disease genes].
Duodecim. 1996;112(24):2358-65.
3
The clinical impact of the Human Genome Project: inherited variants in cancer care.
Ann Oncol. 2002;13 Suppl 4:105-7. doi: 10.1093/annonc/mdf646.
4
Commercial molecular diagnostics in the U.S.: The Human Genome Project to the clinical laboratory.
Hum Mutat. 2002 Apr;19(4):324-33. doi: 10.1002/humu.10061.
5
Rewriting the human prospect.
Healthc Forum J. 1993 Sep-Oct;36(5):24-33.
6
Genetic susceptibility to birth defects in humans: from gene discovery to public health action.
Teratology. 2000 Jan-Feb;61(1-2):17-20. doi: 10.1002/(SICI)1096-9926(200001/02)61:1/2<17::AID-TERA4>3.0.CO;2-X.
7
The Human Genome Project--promise and problems.
J Contemp Health Law Policy. 1994 Fall;11(1):1-21.
8
ACOG technology assessment. Genetics and molecular diagnostic testing. Number 1, July 2002. American College of Obstetrics and Gynecology.
Int J Gynaecol Obstet. 2002 Oct;79(1):67-85.
9
The CDC's EGAPP initiative: evaluating the clinical evidence for genetic tests.
Am Fam Physician. 2009 Dec 1;80(11):1218.
10
The Human Genome Project and eugenics: identifying the impact on individuals with mental retardation.
Ment Retard. 2001 Apr;39(2):158-60. doi: 10.1352/0047-6765(2001)039<0158:THGPAE>2.0.CO;2.
引用本文的文献
1
Cystic fibrosis testing comes of age.
J Mol Diagn. 2009 May;11(3):173-5. doi: 10.2353/jmoldx.2009.090024. Epub 2009 Apr 9.
2
Polymorphisms in the glucocerebrosidase gene and pseudogene urge caution in clinical analysis of Gaucher disease allele c.1448T>C (L444P).
BMC Med Genet. 2006 Aug 3;7:69. doi: 10.1186/1471-2350-7-69.
3
A novel method for creating artificial mutant samples for performance evaluation and quality control in clinical molecular genetics.
J Mol Diagn. 2005 May;7(2):247-51. doi: 10.1016/S1525-1578(10)60551-X.
4
Microsphere bead arrays and sequence validation of 5/7/9T genotypes for multiplex screening of cystic fibrosis polymorphisms.
J Mol Diagn. 2004 Nov;6(4):348-55. doi: 10.1016/S1525-1578(10)60531-4.
本文引用的文献
1
Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testing.
J Mol Diagn. 2003 Nov;5(4):227-30. doi: 10.1016/S1525-1578(10)60478-3.
2
Alternative approaches to proficiency testing in molecular genetics.
Clin Chem. 2003 May;49(5):717-8. doi: 10.1373/49.5.717.
3
NIST physical standards for DNA-based medical testing.
J Clin Lab Anal. 2002;16(1):5-10. doi: 10.1002/jcla.2062.
4
Laboratory standards and guidelines for population-based cystic fibrosis carrier screening.
Genet Med. 2001 Mar-Apr;3(2):149-54. doi: 10.1097/00125817-200103000-00010.
Zotero 插件